Inhibition of cytochrome P450 enhances the nephro- and hepatotoxicity of ochratoxin A.
Bioactivation
Detoxification
Drug metabolism
Metabolic zonation
Mycotoxins
Journal
Archives of toxicology
ISSN: 1432-0738
Titre abrégé: Arch Toxicol
Pays: Germany
ID NLM: 0417615
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
received:
28
08
2022
accepted:
06
10
2022
pubmed:
14
10
2022
medline:
25
10
2022
entrez:
13
10
2022
Statut:
ppublish
Résumé
The mycotoxin ochratoxin A (OTA) is a contaminant in food that causes nephrotoxicity and to a minor degree hepatotoxicity. Recently, we observed that OTA induces liver damage preferentially to the cytochrome P450 (CYP)-expressing pericentral lobular zone, similar to hepatotoxic substances known to be metabolically toxified by CYP, such as acetaminophen or carbon tetrachloride. To investigate whether CYP influences OTA toxicity, we used a single dose of OTA (7.5 mg/kg; intravenous) with and without pre-treatment with the pan CYP-inhibitor 1-aminobenzotriazole (ABT) 2 h before OTA administration. Blood, urine, as well as liver and kidney tissue samples were collected 24 h after OTA administration for biochemical and histopathological analyses. Inhibition of CYPs by ABT strongly increased the nephro- and hepatotoxicity of OTA. The urinary kidney damage biomarkers kidney injury molecule-1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL) were increased > 126-fold and > 20-fold, respectively, in mice treated with ABT and OTA compared to those receiving OTA alone. The blood biomarkers of liver damage, alanine transaminase (ALT) and aspartate transaminase (AST) both increased > 21- and 30-fold, respectively, when OTA was administered to ABT pre-treated mice compared to the effect of OTA alone. Histological analysis of the liver revealed a pericentral lobular damage induced by OTA despite CYP-inhibition by ABT. Administration of ABT alone caused no hepato- or nephrotoxicity. Overall, the results presented are compatible with a scenario where CYPs mediate the detoxification of OTA, yet the mechanisms responsible for the pericental liver damage pattern still remain to be elucidated.
Identifiants
pubmed: 36227364
doi: 10.1007/s00204-022-03395-y
pii: 10.1007/s00204-022-03395-y
pmc: PMC9584869
doi:
Substances chimiques
ochratoxin A
1779SX6LUY
Lipocalin-2
0
Carbon Tetrachloride
CL2T97X0V0
Acetaminophen
362O9ITL9D
Alanine Transaminase
EC 2.6.1.2
Cytochrome P-450 Enzyme System
9035-51-2
Mycotoxins
0
Biomarkers
0
Aspartate Aminotransferases
EC 2.6.1.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3349-3361Informations de copyright
© 2022. The Author(s).
Références
Mycotoxin Res. 2017 Feb;33(1):39-47
pubmed: 27830509
Arch Toxicol. 2022 Nov;96(11):2967-2981
pubmed: 35962801
J Pharm Pharm Sci. 2000 Sep-Dec;3(3):281-91
pubmed: 11177646
Food Chem Toxicol. 2018 Feb;112:320-331
pubmed: 29309824
Chem Res Toxicol. 2005 Aug;18(8):1253-61
pubmed: 16097798
Hepatology. 2021 Apr;73(4):1531-1550
pubmed: 32558958
Natl Toxicol Program Tech Rep Ser. 1989 May;358:1-142
pubmed: 12695783
IEEE Trans Image Process. 1998;7(1):27-41
pubmed: 18267377
Toxicol Sci. 2012 Jun;127(2):315-30
pubmed: 22403158
Toxins (Basel). 2021 Aug 23;13(8):
pubmed: 34437458
Toxicology. 2010 Nov 9;277(1-3):49-58
pubmed: 20816719
Turk J Pharm Sci. 2017 Apr;14(1):90-94
pubmed: 32454599
Arch Toxicol. 2021 Jun;95(6):2163-2177
pubmed: 34003344
EXCLI J. 2016 Dec 23;15:872-874
pubmed: 28275323
Toxicol Appl Pharmacol. 1996 Apr;137(2):182-92
pubmed: 8661343
J Pharmacol Exp Ther. 2009 Jun;329(3):1148-55
pubmed: 19307449
Cell Mol Gastroenterol Hepatol. 2021;11(4):909-933
pubmed: 33189892
Hepatology. 2022 May;75(5):1095-1109
pubmed: 34927748
IARC Monogr Eval Carcinog Risks Hum. 1993;56:489-521
pubmed: 8411629
J Hepatol. 2022 Jul;77(1):71-83
pubmed: 35131407
Crit Rev Toxicol. 2005 Jan;35(1):33-60
pubmed: 15742902
Chem Res Toxicol. 2005 Jul;18(7):1091-7
pubmed: 16022501
Chem Biol Interact. 2006 Jan 5;159(1):18-46
pubmed: 16293235
Nat Methods. 2019 Dec;16(12):1226-1232
pubmed: 31570887
Acta Cir Bras. 2011;26 Suppl 2:106-10
pubmed: 22030824
Toxins (Basel). 2016 Apr 15;8(4):111
pubmed: 27092524
Chem Res Toxicol. 2004 Feb;17(2):234-42
pubmed: 14967011
Med Chem (Los Angeles). 2018;8(3):
pubmed: 30221034
Cells. 2019 Dec 02;8(12):
pubmed: 31810365
Toxins (Basel). 2015 Oct 22;7(10):4253-82
pubmed: 26506387
Arch Toxicol. 2018 Sep;92(9):2963-2977
pubmed: 30039229
Arch Toxicol. 2020 Jan;94(1):205-217
pubmed: 31919559
Chem Res Toxicol. 2005 Jul;18(7):1082-90
pubmed: 16022500
Toxins (Basel). 2016 Jul 04;8(7):
pubmed: 27384585
Mol Nutr Food Res. 2007 Jan;51(1):61-99
pubmed: 17195275
Toxins (Basel). 2021 Oct 22;13(11):
pubmed: 34822534
Sci Rep. 2017 Jul 24;7(1):6224
pubmed: 28740200
J Natl Cancer Inst. 1985 Oct;75(4):733-42
pubmed: 3862905
Mycotoxin Res. 2020 Feb;36(1):1-10
pubmed: 31077038
Hepatol Commun. 2022 Jan;6(1):161-177
pubmed: 34558834
Nat Metab. 2021 Sep;3(9):1228-1241
pubmed: 34552267
Mol Nutr Food Res. 2008 Apr;52(4):472-82
pubmed: 18381679
Mol Nutr Food Res. 2009 Apr;53(4):467-78
pubmed: 19072886
Gan. 1978 Aug;69(4):599-600
pubmed: 710809
Arh Hig Rada Toksikol. 2012 Dec;63(4):417-27
pubmed: 23334036
Cells. 2021 Sep 23;10(10):
pubmed: 34685496
J Hepatol. 2016 Apr;64(4):860-71
pubmed: 26639393